Document is current
Any future updates will be listed below
-
Authors
Costa, Rodrigo Donato
Thomaz Neto, Farid José https://orcid.org/0000-0002-4816-5838
Moustafa, M. Tarek
Atilano, Shari R.
Chwa, Marilyn
Cáceres-del-Carpi, Javier
Mohamed, Mohamed Hamid
Kenney, M. Cristina
Kuppermann, Baruch D.
-
Funding
Funding for this research was provided by:
Institute for Clinical and Translational Science, University of California, Irvine
Research to Prevent Blindness
- License Information
-
More Information
Article History
Received: 10 March 2023
Accepted: 15 June 2023
First Online: 25 July 2023
Declarations
:
: Not applicable.
: Not applicable.
: Rodrigo Donato Costa: No competing interests Farid José Thomaz Neto: No competing interests M. Tarek Moustafa: No competing interests Shari R. Atilano: No competing interests Marilyn Chwa: No competing interests Javier Cáceres-del-Carpi: No competing interests Mohamed Hamid Mohamed: No competing interests M. Cristina Kenney: No competing interests Baruch D. Kuppermann: Clinical Research: Allegro Ophthalmics, Allergan, Genentech Inc, Ionis, IVERIC Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, RegenXBio Consultant: Allegro Ophthalmics, Allergan, Aviceda Therapeutics, Clearside, EyeBio, Eyedaptic, Genentech Inc, Glaukos Corporation, InflammX Therapeutics, IVERIC Bio, jCyte, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, ReVana Therapeutics, Ripple Therapeutics, Theravance Biopharma Speaker Bureau: Allergan, Genentech.
